Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available.
The DUSC considered:
- Golimumab - axial spondyloarthritis
- Nivolumab and ipilimumab - renal cell carcinoma
- Pembrolizumab - bladder cancer
- Bictegravir sodium with emtricitabine and tenofovir alafenamide fumarate - HIV infection
- Dolutegravir sodium with rilpivirine hydrochloride - HIV infection
- Anti-retroviral medicines - HIV infection
- Tolvaptan - polycystic kidney disease
